FDA Panel Votes Against Two Cancer Indications but Backs 4 of 6

Federal advisers this week supported the efforts of pharmaceutical companies in 4 of 6 cases in which these firms are fighting to maintain cancer indications for approved drugs. They voted against them in two cases.

The staff of the US Food and Drug Administration (FDA) will now consider these votes as they decide what to do regarding the six cases of what they have termed “dangling” accelerated approvals.

“One of the reasons I think we’re convening today is to prevent these accelerated approvals from dangling ad infinitum,” commented one of the members of the advisory panel.